Clinico-pathological and Genomic Features of HER2-low Early Breast Cancer
Clinico-pathological and Genomic Features of HER2-low Early Breast Cancer (eBC). Results of Retrospective Analysis of Seven Adjuvant Trials by the Hellenic Cooperative Oncology Group (HeCOG)
Although breast cancer remains one of the most common and fatal cancer types among women worldwide, earlier diagnosis and improved therapeutic approaches have led to decreased mortality over last years. Indeed, the use of HER2-targeted drugs has improved clinical outcomes for patients with HER2 positive breast cancer, while, on the other hand, until recently, little progress has been made for HER2-negative (IHC score 0 and 1+) patients.
However, it seems that among these HER2-negative breast cancers, substantial heterogeneity exists regarding the expression of hormone receptors (HR) and HER2.
Biomarkers are critical for translating the biological heterogeneity of breast cancer into prognostically and therapeutically useful information. In recent years gene expression profiling and genomic analysis have shown utility in specific clinical scenarios, but immunohistochemistry (IHC) remains the cornerstone of biomarker testing in both early and advanced/metastatic disease.
In breast cancer, achieving efficacy with endocrine therapy or with HER2-blockade requires identifying patients whose tumors show significant survival dependency on the therapeutic target. This is achieved by using appropriate biomarkers cut-offs ensuring a favorable benefit-to-toxicity ratio for specific patients.
This paradigm has recently been challenged by a new class of HER2 drugs that use target expression not as a direct molecular lever but as a vehicle to deliver potent agents to cancer cells, breaking the straightforward link between the molecular target and the corresponding therapy. These drugs exhibit impressive activity at marker expression levels much lower than those required to effectively block HER2 signaling, shifting the diagnostic focus to the lower end of the staining spectrum, specifically distinguishing between HER2-zero and HER2-low expression.
Given the lack of a definitive molecular hallmark for cancers characterized by low HER2 expression, ongoing efforts aim to understand the biology of this heterogeneous group of tumors. This understanding is crucial to triage treatment, investigate resistance mechanisms, and inform potential combination strategies.
To enrich the available data, we perform a retrospective analysis of HER2-low patients in a large cohort of early breast cancer patients from Greece enrolled in 7 randomized and observational clinical studies.
Given the importance of the hormone receptors and the known differential distribution of ER/PgR status between HER2-zero, HER2-low and HER2-positive breast tumors, after analyzing the entire population cohort, ER/PgR status will be treated as a confounding variable in the analysis and the HER2 categories will be compared separately within ER/PR-positive and ER/PR-negative disease.
The study aims to investigate how HER2-zero, HER2-low and HER2-positive tumors are distributed across ER expression categories. Additionally, we will evaluate whether PgR positivity varies across ER expression categories, and if PgR identify heterogeneity within ER-low tumors.
As TP53 mutation is strongly linked to basal-like, high-grade, hormone receptor-negative and HER2-positive biology, we will examine if TP53 mutation frequency differs across ER categories and classic subtypes and if PIK3CA mutation frequency differs across ER categories and PgR-defined groups, as PIK3CA mutations are generally enriched in luminal breast cancer.
TIL biology is also strongly subtype-dependent. TNBC and HER2-positive disease are generally more immune-enriched than luminal disease, so we will examine if stromal TIL levels are associated with ER category, HER2 category and classic subtype in our study.
Summarizing, our aim is to evaluate if HER2-low status retains independent associations with clinicopathologic, immune or genomic features after adjustment for ER category and classic subtype, whether ER/HER2 matrix groups are associated with disease outcome, and associations remain after adjustment for standard prognostic factors and treatment.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Detaillierte Beschreibung
From 1996 until 2020, 5,320 eligible patients with operable breast cancer were treated, within the context of 3 randomized and 4 observational clinical studies with dds-CT including taxanes and anthracyclines. Adjuvant hormonal and radiation treatment were administered, as indicated.
IHC and FiSH data from patients enrolled in the above randomized phase III trials conducted by the Hellenic Cooperative Oncology Group (HeCOG) will be retrospectively reviewed.
All patients have signed a study-specific written informed consent before randomization, consenting for the trial and permitting the use of their biological material for future research purposes. All studies were conducted in accordance with the Declaration of Helsinki.
Tumor material is examined mainly on tissue microarrays (TMA). Although, there is a HER2 assessment from local pathology laboratories, all tumors are re-evaluated centrally for ER, PgR and HER2 in the laboratory of Molecular Oncology according to ASCO/CAP guidelines. Tumors are subtyped with immunohistochemistry (IHC4) for ER, PgR, HER2 and Ki67. FISH is performed for the assessment of HER2 gene status. IHC for EGFR and CK5 is used for the classification of basal-like tumors; the expression of CD8 on TILs is also evaluated. Moreover, we investigate the mutational profile of Greek women with breast cancer, via the application of DNA Next Generation Sequencing (NGS) technologies, relative also to patient outcome.
Patient demographic, clinicopathological and treatment data are available in all cases.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Kontakte und Standorte
Studienorte
-
-
-
Athens, Griechenland, 11526
- Hellenic Cooperative Oncology Group (HeCOG)
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
patients with operable breast cancer treated with dds-CT including taxanes and anthracyclines. Adjuvant hormonal and radiation treatment were administered, as indicated
Beschreibung
Inclusion Criteria:
- Age 18 and above
- Histologically confirmed BC
- All treated with adjuvant dose-dense sequential chemotherapy (dds-CT)
- Tumor tissue specimen (FFPE) availability
Exclusion Criteria:
- not adequate, and unsuitable tissue for IHC, FISH, NGS analysis
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: RETROSPECTIVE
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall Survival (OS)
Zeitfenster: Time from study entry to death from any cause, assessed up to 120 months]
|
To investigate the long-term prognostic significance of HER2 positive, HER2 low and HER2 zero in terms of OS |
Time from study entry to death from any cause, assessed up to 120 months]
|
|
Disease-Free Survival (DFS)
Zeitfenster: Time from study entry to first recurrence (local, regional, distant) or death from any cause, whichever comes first, assessed up to 120 months]
|
To investigate the long-term prognostic significance of HER2 positive, HER2 low and HER2 zero in term of DFS |
Time from study entry to first recurrence (local, regional, distant) or death from any cause, whichever comes first, assessed up to 120 months]
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Schettini F, Chic N, Braso-Maristany F, Pare L, Pascual T, Conte B, Martinez-Saez O, Adamo B, Vidal M, Barnadas E, Fernandez-Martinez A, Gonzalez-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavila J, Barrios CH, Lluch A, Martin M, Locci M, De Placido S, Prat A. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021 Jan 4;7(1):1. doi: 10.1038/s41523-020-00208-2.
- Curigliano G, Dent R, Earle H, Modi S, Tarantino P, Viale G, Tolaney SM. Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer. ESMO Open. 2024 Apr;9(4):102989. doi: 10.1016/j.esmoop.2024.102989. Epub 2024 Apr 12.
- Patel A, Unni N, Peng Y. The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer. Cancers (Basel). 2020 Jul 28;12(8):2081. doi: 10.3390/cancers12082081.
- Jokhadze N, Das A, Dizon DS. Global cancer statistics: A healthy population relies on population health. CA Cancer J Clin. 2024 May-Jun;74(3):224-226. doi: 10.3322/caac.21838. Epub 2024 Apr 4. No abstract available.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- HE_10L/25
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .